Show simple item record

dc.contributor.authorLee, MY
dc.contributor.authorFraser, JD
dc.contributor.authorChapman, MJ
dc.contributor.authorSundararajan, K
dc.contributor.authorUmapathysivam, MM
dc.contributor.authorSummers, MJ
dc.contributor.authorZaknic, AV
dc.contributor.authorRayner, CK
dc.contributor.authorMeier, JJ
dc.contributor.authorHorowitz, M
dc.contributor.authorDeane, AM
dc.date.accessioned2020-12-17T04:30:20Z
dc.date.available2020-12-17T04:30:20Z
dc.date.issued2013-10-01
dc.identifierpii: dc13-0307
dc.identifier.citationLee, M. Y., Fraser, J. D., Chapman, M. J., Sundararajan, K., Umapathysivam, M. M., Summers, M. J., Zaknic, A. V., Rayner, C. K., Meier, J. J., Horowitz, M. & Deane, A. M. (2013). The Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically Ill. DIABETES CARE, 36 (10), pp.3333-3336. https://doi.org/10.2337/dc13-0307.
dc.identifier.issn0149-5992
dc.identifier.urihttp://hdl.handle.net/11343/255338
dc.description.abstractOBJECTIVE: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have additive insulinotropic effects when coadministered in health. We aimed to determine whether GIP confers additional glucose lowering to that of GLP-1 in the critically ill. RESEARCH DESIGN AND METHODS: Twenty mechanically ventilated critically ill patients without known diabetes were studied in a prospective, randomized, double-blind, crossover fashion on 2 consecutive days. Between T0 and T420 minutes, GLP-1 (1.2 pmol/kg·min(-1)) was infused intravenously with either GIP (2 pmol/kg·min(-1)) or 0.9% saline. Between T60 and T420 minutes, nutrient liquid was infused into the small intestine at 1.5 kcal/min. RESULTS: Adding GIP did not alter blood glucose or insulin responses to small intestinal nutrient. GIP increased glucagon concentrations slightly before nutrient delivery (P=0.03), but not thereafter. CONCLUSIONS: The addition of GIP to GLP-1 does not result in additional glucose-lowering or insulinotropic effects in critically ill patients with acute-onset hyperglycemia.
dc.languageEnglish
dc.publisherAMER DIABETES ASSOC
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleThe Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically Ill
dc.typeJournal Article
dc.identifier.doi10.2337/dc13-0307
melbourne.affiliation.departmentMedicine (RMH)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleDiabetes Care
melbourne.source.volume36
melbourne.source.issue10
melbourne.source.pages3333-3336
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1338267
melbourne.contributor.authorDeane, Adam
dc.identifier.eissn1935-5548
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record